To grasp safety, we must always be vigilant and guard against micro-failure.
Release time:
2020-08-14
To grasp safety, one must always be vigilant and guard against the slightest failure
■ This newspaper commentator
"Safety is a big thing". Jiang Xiaomeng, chairman of the group company, recently visited the international trading company and interviewed the person in charge of the relevant leasing unit. This sentence seems to be a cliché, but no one can deny that whether it is the development of society or the progress of the enterprise, "Safety" is the first prerequisite.
As far as business operations are concerned, the ultimate goal is of course to obtain profits, create more value for society, and enable employees to get more benefits. In today's fierce market competition, development is undoubtedly the first priority of each enterprise, and security is the most reliable guarantee for the development of enterprises. Just imagine, for an enterprise that has accidents at regular intervals and everyone is in danger, how much energy will the enterprise operators have to formulate strategies and plan for the future? How much sense of belonging will employees have to the enterprise, how much sense of responsibility and dedication will they have to their work? No matter how hyped the talk about development is, it will only be a moon in the water and a flower in the mirror.
Do a good job in safety management. Pre-prevention is more reliable, more effective, more trivial and easier to ignore than post-investigation and assessment. Just like the cause of Chairman Jiang Xiaomeng's interview, it was only a few inconspicuous cigarette butts at the warehouse site, but behind the cigarette butts were the weak safety awareness of the employees of the relevant units, the lack of safety behavior habits, and the lack of safety management. In 2016 , all enterprises of the group carried out self-examination and self-correction activities of "anti-habitual violations". Hundreds of items were found out, and piles and piles were seemingly trivial "small" things. These problems are more hidden and potentially harmful because of their "small". If an accident occurs due to any of the habitual violations, it will bring great losses to the enterprise and the employees' families. Therefore, safety management is not only the primary work of enterprise managers, but also the primary work of every employee. Only when the company's various safety management requirements become the conscious norms of every employee, let it become the instinct of every employee to find and correct potential safety hazards, let standardized operation and compliance with the system become the behavior habits of every employee, and let accident emergency handling become every employee's necessary skills, can the safety management of the enterprise be truly implemented.
This year, the establishment of a safety, environmental protection and accident-free factory has once again been fully launched in the company. The annual safety meeting also emphasizes that "hidden dangers are accidents" and "safety and environmental protection management with a' zero tolerance' attitude". This all requires us to be vigilant at all times, "intensively cultivate" safety management and eliminate hidden dangers from 1.1 minor mistakes. Because, only safety is guaranteed, the foundation of our enterprise development can not be shaken.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page